When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...
Please provide your email address to receive an email when new articles are posted on . A new artemether-lumefantrine dispersible tablet was just as effective as the crushed standard tablet in ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (zanubrutinib) for all existing indications, halving the required daily pill ...
BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
In this interview, the main uses and benefits of NIR spectroscopy in tableting are discussed. Oral-solid dosage (OSD) forms remain a popular choice for both pharmaceutical companies and patients.
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new ...
The Food and Drug Administration initially approved the chewable tablet formulation in January 2017. Vyvanse (lisdexamfetamine dimesylate; Shire) is now available as chewable tablets for the treatment ...
This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
BASEL, Switzerland--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results